Halia Therapeutics
Salt Lake City, UT · Biotechnology · 27 employees
Halia is a clinical-stage biopharmaceutical company discovering and developing novel therapies to improve the lives of patients with inflammatory disorders and neurological diseases. We do this by advancing innovative medicines that target the immune system's response to resolve chronic inflammation and eliminate the damage caused by aberrantly activated immune responses.
Funding history
- Series seed — $337K — Jul 2025
- Funding Round — $30.0M — Jan 2024
- Funding Round — $12.2M — Dec 2022
- Funding Round — $5.0M — Feb 2021
- Funding Round — $6.3M — Oct 2020
Recent signals
- May 12, 2026: Halia Therapeutics Appoints Han Myint as Chief Medical Officer
- Oct 06, 2025: Halia Therapeutics Appoints Paul Jones as Chief Strategy Officer & GM
- Jul 16, 2025: Raised $337K in Series seed
- Jan 31, 2024: Raised $30.0M
- Dec 30, 2022: Raised $12.2M
- Feb 17, 2021: Raised $5.0M
- Oct 22, 2020: Raised $6.3M
See plans & pricing → Track Halia Therapeutics’s funding, hiring, and signals — with verified contacts — on Fundz.